« Previous Next » European Urology
Volume 50, Issue 5 , Pages 1086-1095 , November 2006

Extended Duration of Efficacy of Vardenafil When Taken 8 Hours Before Intercourse: A Randomized, Double-Blind, Placebo-Controlled Study

Hartmut Porst
- Urological Practice, Hamburg, Germany
- Corresponding author. Urological Practice, Neuer Jungfernstieg 6a, 20354 Hamburg, Germany. Tel. +49 40 34 61 84; Fax: +49 40 35 11 17.
Ira D. Sharlip
- University of California, San Francisco, California, USA
Dimitris Hatzichristou
- Aristotle University of Thessaloniki, Thessaloniki, Greece
Eusebio Rubio-Aurioles
- Asociación Mexicana Para la Salud Sexual, Tlalpan, Mexico
Marc Gittelman
- South Florida Medical Research, Aventura, Florida, USA
Britt-Nicole Stancil
- GlaxoSmithKline, Research Triangle Park, North Carolina, USA
Peter M. Smith
- GlaxoSmithKline, Research Triangle Park, North Carolina, USA
H. Jeffrey Wilkins
- GlaxoSmithKline, King of Prussia, Pennsylvania, USA
Peter Pommerville
- Can-Med Clinical Research Inc., Victoria, British Columbia, Canada
for the Vardenafil Study Group

,Accepted 18 May 2006.

Patient disposition and reasons for withdrawal.

Patient disposition and reasons for withdrawal.
- Full-Size Image
- Download to PowerPoint
LS mean success rates for maintaining an erection that led to successful sexual intercourse (SEP3) and inserting the penis into the partner's vagina (SEP2) at baseline and overall for weeks 2–10 (the

LS mean success rates for maintaining an erection that led to successful sexual intercourse (SEP3) and inserting the penis into the partner's vagina (SEP2) at baseline and overall for weeks 2–10 (the period after the initial titration phase). LS=least squares; SEP=Sexual Encounter Profile Question.
- Full-Size Image
- Download to PowerPoint
Overall mean success rates during weeks 2–10 (the period after the initial titration phase) for (1) maintaining an erection that led to successful sexual intercourse (SEP3) and (2) inserting the penis

Overall mean success rates during weeks 2–10 (the period after the initial titration phase) for (1) maintaining an erection that led to successful sexual intercourse (SEP3) and (2) inserting the penis into the partner's vagina (SEP2) at hourly intervals 6–10hours postdose. SEP=Sexual Encounter Profile Question.
- Full-Size Image
- Download to PowerPoint
LS mean IIEF-EF domain scores at baseline and after the initial titration phase at weeks 2–6, 6–10 and week 10 LOCF (intent-to-treat population). LS=least squares; IIEF-EF=International Index of Erect

LS mean IIEF-EF domain scores at baseline and after the initial titration phase at weeks 2–6, 6–10 and week 10 LOCF (intent-to-treat population). LS=least squares; IIEF-EF=International Index of Erectile Function-Erectile Function; LOCF=last observation carried forward.
- Full-Size Image
- Download to PowerPoint
Percentage of patients with a positive response to the GAQ (“Has the treatment you have been taking over the last 4 weeks improved your erections? (Y/N)”) after the initial titration phase at weeks 2–

Percentage of patients with a positive response to the GAQ (“Has the treatment you have been taking over the last 4 weeks improved your erections? (Y/N)”) after the initial titration phase at weeks 2–6, 6–10 and week 10 LOCF (intent-to-treat population). GAQ=Global Assessment Question; LOCF=last observation carried forward.
- Full-Size Image
- Download to PowerPoint